7WN0

Structure of PfENT1(Y190A) in complex with nanobody 19

Summary for 7WN0

• Entry DOI: 10.2210/pdb7wn0/pdb
• EMDB information: 32618
• Descriptor: Equilibrative nucleoside/nucleobase transporter, nanobody19 (2 entities in total)
• Functional Keywords: malaria, nucleoside transporter, transport protein
• Biological source: Plasmodium falciparum (malaria parasite P. falciparum); More
• Total number of polymer chains: 2
• Total formula weight: 60760.32

Authors

Wang, C.,Deng, D.,Ren, R.B.,Yu, L.Y. (deposition date: 2022-01-17, release date: 2023-02-01, Last modification date: 2023-08-16)

Primary citation

Wang, C.,Yu, L.,Zhang, J.,Zhou, Y.,Sun, B.,Xiao, Q.,Zhang, M.,Liu, H.,Li, J.,Li, J.,Luo, Y.,Xu, J.,Lian, Z.,Lin, J.,Wang, X.,Zhang, P.,Guo, L.,Ren, R.,Deng, D.
Structural basis of the substrate recognition and inhibition mechanism of Plasmodium falciparum nucleoside transporter PfENT1.
Nat Commun, 14:1727-1727, 2023

PubMed Abstract: By lacking de novo purine biosynthesis enzymes, Plasmodium falciparum requires purine nucleoside uptake from host cells. The indispensable nucleoside transporter ENT1 of P. falciparum facilitates nucleoside uptake in the asexual blood stage. Specific inhibitors of PfENT1 prevent the proliferation of P. falciparum at submicromolar concentrations. However, the substrate recognition and inhibitory mechanism of PfENT1 are still elusive. Here, we report cryo-EM structures of PfENT1 in apo, inosine-bound, and inhibitor-bound states. Together with in vitro binding and uptake assays, we identify that inosine is the primary substrate of PfENT1 and that the inosine-binding site is located in the central cavity of PfENT1. The endofacial inhibitor GSK4 occupies the orthosteric site of PfENT1 and explores the allosteric site to block the conformational change of PfENT1. Furthermore, we propose a general "rocker switch" alternating access cycle for ENT transporters. Understanding the substrate recognition and inhibitory mechanisms of PfENT1 will greatly facilitate future efforts in the rational design of antimalarial drugs.

PubMed: 36977719
DOI: 10.1038/s41467-023-37411-1

Experimental method

ELECTRON MICROSCOPY (3.64 Å)